导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -9.74% | 3793/4773 |
| 近一周 | -2.04% | 2200/5458 |
| 近一月 | -0.08% | 850/5421 |
| 近一季 | 3.52% | 405/5205 |
| 近半年 | -7.31% | 3271/4920 |
| 近一年 | -13.15% | 3622/4361 |
| 近两年 | 9.11% | 2817/2954 |
| 近三年 | -8.34% | 2031/2253 |
| 成立以来 | 20.17% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.60% 3888/4961 |
-12.67% 4425/5312 |
- - |
- - |
| 2025 | 0.59% 3256/4813 |
0.32% 1905/3635 |
-3.42% 3435/4076 |
5.62% 3575/4524 |
-1.70% 2997/4813 |
| 2024 | 8.26% 1575/3463 |
5.14% 400/2808 |
-5.04% 1624/3014 |
15.28% 1762/3129 |
-5.94% 2611/3463 |
| 2023 | -14.55% 1608/2656 |
2.14% 1434/2280 |
-9.88% 2077/2385 |
-2.26% 648/2515 |
-5.02% 1239/2655 |
| 2022 | -15.65% 425/2207 |
-18.81% 1398/1919 |
16.54% 150/2016 |
-11.62% 552/2113 |
0.86% 1438/2208 |
| 2021 | -12.26% 1126/1822 |
-3.99% 841/1255 |
-0.10% 1126/1330 |
-11.89% 1280/1466 |
3.82% 387/1822 |
| 2020 | - - |
- - |
- - |
16.45% 152/1164 |
22.41% 45/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 富国中证消费50ETF联接C VS. 长安沪深300非周期A(740101) |